HDAC9 and tropical spastic paraparesis: Figure 3), providing a molecular mechanism for the increased female HAM susceptibility. In addition, in silico identification of HDAC inhibitors entinostat, vorinostat and panabinostat confirm promising preclinical findings on the use of this drug class to treat HTLV-1 infection and possibly HAM patients36. Of interest, the older HDAC inhibitor valproate, which is safe but ineffective in HAM patients37 was not significantly enriched in our analysis.